Quince Therapeutics, Inc. (QNCX) intrinsic value & 10-year financials
Quince Therapeutics, Inc. (QNCX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Revenue (FY2025)
- —
- Revenue growth (9-yr CAGR)
- 16.4%
- ROIC (10-yr avg)
- -149.7%
- Free cash flow (FY2025)
- -$41.8M
QNCX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$84.0M | -$1.68 | -$41.8M | — | -750.1% |
| FY2024 | — | -$56.8M | -$1.31 | -$32.2M | — | -98.1% |
| FY2023 | — | -$31.4M | -$0.84 | -$18.5M | — | -51.6% |
| FY2022 | $262.0K | -$51.7M | -$1.54 | -$44.2M | -19853.1% | -98.3% |
| FY2021 | $225.0K | -$89.9M | -$3.03 | -$63.1M | -40141.3% | -94.8% |
| FY2020 | — | -$76.8M | — | -$50.9M | — | -55.8% |
| FY2019 | — | -$37.0M | — | -$33.3M | — | -94.5% |
| FY2018 | — | -$12.5M | — | -$11.9M | — | 45.8% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Quince Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Quince Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -56.9% ROIC.
Quince Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Quince Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-55.80 per share.